Wall Street Zen Upgrades Inhibrx Biosciences (NASDAQ:INBX) to "Hold"
Wall Street Zen has upgraded Inhibrx Biosciences (NASDAQ:INBX) from a "Sell" to a "Hold" rating, bringing the consensus rating for the stock to "Hold" with an average price target of $150. This upgrade comes despite the company reporting a quarterly loss of $2.15 per …